On September 3rd, FTSE Russell announced quarterly review changes for the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, FTSE China A400 Index, etc. These changes will take effect after the market closes on Friday, September 19, 2025 (i.e., Monday, September 22, 2025).
Taking the FTSE China A50 Index as an example, Beigene-U, Eoptolink, WuXi AppTec, Zhongji Innolight have been added to the constituent stock list, while China National Nuclear Power, China Unicom, Guodian NARI, Wanhua Chemical have been removed. Additionally, if any constituent stocks are removed, they will be supplemented from China Minmetals Bank, Luoyang Molybdenum, Tonghuashun, SAIC Motor, and Seres.
In simple terms, multiple stocks from the innovative drug and CPO sectors have been included in the FTSE China A50 Index, while some traditional dividend stocks have been removed.
The FTSE website indicates that the FTSE China A50 Index is a real-time tradable index composed of the 50 largest A-share companies. The constituent stocks must comply with foreign ownership restrictions (i.e., not exceeding the foreign shareholding limit) and must meet the eligibility criteria for the northbound Shanghai-Hong Kong Stock Connect program (implemented since the quarterly review in June 2022).
At the same time, the constituents of the FTSE China A150 Index have also changed, with China National Nuclear Power, China Unicom, Hua Hong Semiconductor, Guodian NARI, Shengyi Technology, Shenzhen South China Circuit, Dongshan Precision, Tianfu Communication, Shenghong Technology, Wanhua Chemical being included, while Beigene-U, Shouchao Securities, Eoptolink, Huadian International, Huayu Automotive, Aimeike, Jinshiyuan, JinkoSolar, WuXi AppTec, Zhongji Innolight have been removed.
It can be seen that stocks such as Beigene-U, Eoptolink, WuXi AppTec, and Zhongji Innolight have entered the FTSE China A50 Index due to their strong performance within the year.
Risk Warning and Disclaimer
The market has risks, and investment should be cautious. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at their own risk

300308

300502

688235

BGNE

06160

603259

02359

On September 3rd, FTSE Russell announced the quarterly review changes for the FTSE China 50 Index, which will take effect on September 22, 2025. New stocks such as BeOne Medicines, Eoptolink, WuXi AppTec, and Zhongji Innolight have been included, while traditional dividend stocks like China National Nuclear Power have been removed. The FTSE China A50 Index consists of the 50 largest A-share companies and must comply with foreign ownership restrictions and the qualifications for the northbound Shanghai-Hong Kong Stock Connect. The market has risks, and investment should be cautious

- On September 3, FTSE Russell announced quarterly changes to several indices, including the FTSE China 50 and FTSE China A50, effective after market close on September 19, 2025.  
- Notable additions to the FTSE China A50 include BeiGene, Neway, WuXi AppTec, and Zhongji Xuchuang, while China National Nuclear, China Unicom, Guodian NARI, and Wanhua Chemical were removed.  
- The changes reflect a shift towards innovative pharmaceuticals and CPO sectors, with traditional dividend stocks being excluded, highlighting the dynamic nature of the index composition.

Wallstreetcn

Zhongji Innolight

Eoptolink

BeOne Medicines

Beigene

BEONE MEDICINES

WuXi AppTec

WUXI APPTEC

Four popular stocks this year will be included, and the FTSE A50 Index will change its constituent stocks